1. Home
  2. INLX vs ATOS Comparison

INLX vs ATOS Comparison

Compare INLX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

HOLD

Current Price

$5.66

Market Cap

26.4M

Sector

Technology

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$2.59

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
ATOS
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.4M
24.1M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
INLX
ATOS
Price
$5.66
$2.59
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
857.0
52.8K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,336.00
$1,758.00
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.21
$0.53
52 Week High
$12.48
$7.56

Technical Indicators

Market Signals
Indicator
INLX
ATOS
Relative Strength Index (RSI) 48.05 53.25
Support Level $5.37 $0.58
Resistance Level $7.87 $2.60
Average True Range (ATR) 0.14 0.20
MACD 0.06 0.05
Stochastic Oscillator 60.96 56.12

Price Performance

Historical Comparison
INLX
ATOS

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Share on Social Networks: